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doi:10.1016/j.ejvs.2010.08.010Abstract Objectives: Ultrasound-guided foam sclerotherapy (UGFS) is a technique in which
a mixture of sclerosing drug and gas is used to treat varicose veins. Several authors have
demonstrated transient systemic effects after UGFS. These effects are not well understood
but probably originate from a systemic distribution of the sclerosing foam. Therefore, safety
measures have been developed to prevent foam from flowing into the deep venous system.
The aim of the study is to evaluate whether blockage of the saphenofemoral (SF) junction
by either manual compression or surgical ligation prevents microbubbles from leaking into
the deep venous circulation.
Methods: To detect the distribution of microbubbles, radioactive pertechnetate (99mTcO4
) was
added to the foam solution. Initially, in vitro trials were performed in the laboratory to inves-
tigate the effect of 99mTc on foam stability. The time taken for foam to liquefy was measured
for foam alone and for the mixture with 99mTc. In subsequent research, eight varicose great
saphenous veins (GSVs) were treated by UGFS. In three patients, this treatment was preceded
by surgical ligation of the SF junction. In three patients, the groin was manually compressed
during UGFS. In two patients, UGFS was performed without compression of the groin.en, MD, Department of Dermatology, Albert Schweitzer Ziekenhuis, Van Der Steenhovenplein 1, 3317
þ31 43 3877292; fax: þ31 43 3877293.
com (R.P.M. Ceulen).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Blocking the SFJ During Foam Sclerotherapy 773Results: In vitro, 99mTc did not influence foam stability; after 2.6 min all foam had reduced to
liquid, regardless of whether 99mTc had been added or not. In vivo trials showed that all
patients showed a decrease in the cumulative amount of 99mTc detected in the GSV following
polidocanol-99mTc mixture injection. However, the decrease of radioactivity was slightly
reduced when compression or ligation of the SF junction was performed.
Conclusions: Blocking the SF junction during UGFS using either manual compression or ligation
does not prevent, but may reduce the flow of foam into the femoral vein.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Venous insufficiency of the lower limb is a common
phenomenon, with varicose veins appearing as a hallmark
of this condition. It is estimated that the prevalence of
incompetent veins varies from <1% to 73% in women and
from 2% to 56% in men, with the highest reported rates in
Western countries.1,2 Venous incompetence has a strong
impact on health-related quality of life and is associated
with increasing health-care costs.3
Surgery has been the main treatment of varicose veins
for years. However, several less-invasive techniques have
recently been developed. One of these is ultrasound-guided
foam sclerotherapy (UGFS). In UGFS, a sclerosing foam is
injected into the varicose vein. This causes endothelial
damage, leading to sclerothrombus formation and resulting
in occlusion of the vein.
To date, discussions about the safety of foam have not
been conclusive. Gillet et al. described 27 systemic side
effects in 1025 patients, with side effects varying from
migraine to transient ischaemic attack.4 Guex et al. reported
49 incidents during 12,173 polidocanol (POL) liquid and foam
treatments, most of which were visual disturbances.5
The above-mentioned side effects may be caused by the
systemic distribution of foam. Fundamental research,
however, demonstrated that sclerosants are rapidly neu-
tralised by plasma proteins after injection.6 To date, no
research has been able to track the sclerosing gas after
injection. However, several authors have published results
indicating systemic distribution of sclerosant after UGFS.
Ceulen andWright identifiedmicro-emboli in the right atrium
and ventricle of the heart shortly after foam therapy.7,8
Because the side effects are believed to be caused by
a systemic distribution of foam, preventive measures have
been taken to stop foam from leaking into the deep venous
system. Manual compression of the groin is one of the
techniques believed to reduce this leakage. Of the vascular
surgeons in the United Kingdom responding to a question-
naire, 63% stated they gave direct pressure to the junction
during foam sclerotherapy.9
In this article, we aimed to assess whether blocking the
saphenofemoral (SF) junction reduces foam from entering
the deep venous system.
Methods
To visualise small foam particles unseen by duplex, we
mixed POL 1% with pertechnetate (99mTcO4
), a radioactive
substance. Pertechnetate is among the materials used as
a flow tracer, for example, to evaluate the function of the
left ventricle of the heart.10 Using a gamma camera, the
99mTc allows for the detection of foam in the treated veinand leakage from the treated vein into the deep venous
system. We used an average of 140 MBq 99mTc, which
resulted in an effective dose to the patient of about
1.8 mSv. For comparison, the effective dose due to natural
radiation in the Netherlands is 2.0 mSv year.
Before using POLe99mTc foam, we wanted to be sure
that pertechnetate would not influence foam stability.
Therefore, foam half-life was measured for both the stan-
dard foam used in UGFS and the pertechnetate-labelled
POLe99mTc foam.
POLe99mTc mixture preparation
The following standardised technique was employed to
prepare POLe99mTc foam and measure its stability.11 A
sterile 6-ml syringe was used to draw up 1.0 ml of POL 1%
liquid and a sterile 1.0-ml syringe was used to draw up
0.5 ml of pertechnetateesaline solution. The pertechne-
tateesaline solution was mixed with POL 1% using a stain-
less steel two-way connector. A sterile 6-ml syringe with
4.0 ml of air was connected by a three-way connector (BD
Connecta Luer-Lok 360 Becton Dickinson Infusion Therapy
AB, SE 251 06 Helsingborg, Sweden) to the 6-ml syringe with
the 1.5-ml POLe99mTc mixture. Using the Tessari tech-
nique, the sclerosante99mTc and air were drawn back and
forth with 20 pump movements to produce 5.5 ml of scle-
rosing 99mTc-foam.
In vitro experiment e POLe99mTc mixture stability
versus POL stability
Standard foam was made using the Tessari technique, as
described above. Although we do not normally do so, we
added 0.5 ml of 0.9% saline solution to prepare foam in this
study. We used the saline solution because the sclerosing
foams used in this study are not intended to provide
a therapeutic effect; rather, they are intended to be used
for imaging the distribution pattern of foam after injection.
By using a 0.9% saline solution for the production of stan-
dard foam, we enlarged the homogeneity and compara-
bility of both sclerosing foams. Then, a sterile 6-ml syringe
was used to draw up 1.0 ml of POL 1% and 0.5 ml of 0.9%
saline. This 1.5 ml POLesaline solution was mixed with
4.0 ml of air to produce the foam. With 5.5 ml of foam
filling the 6-ml syringe, the syringe was disconnected from
the three-way connector and placed vertically, with the
rubber piston of the syringe at the bottom; and the timer
was started. As the foam degenerated back into its
constituents, the sclerosing solution was found to gradually
re-form at the bottom of the syringe. When the bottom of
774 R.P.M. Ceulen et al.the solution’s meniscus attained a volume of exactly
0.75 ml (half of the original sclerosing volume of 1.5 ml),
the timer was stopped, and the time in seconds was
recorded. This time was defined as the half-life of foam
(T½). The time that was needed for POL foam to return into
liquid completely was also recorded (T1). This process was
repeated for the POLe99mTc mixture (Table 1). All record-
ings were performed at an ambient temperature of 20 C.
In vivo experiment e treating the great saphenous
vein (GSV) with POLe99mTc foam
Treatment groups
A randomly selected group of outpatients with primary iso-
lated great saphenous vein (GSV) incompetence was used.
Eight limbs of eight patients (all female, mean age 51 years)
were assigned to three groups: group 1 was treated with
ligation of the SF junction followed by POLe99mTc UGFS 14
days after operation. Group 2 was administered the
POLe99mTc UGFS under manual compression of the groin.
Group 3 (control group) was given the POLe99mTc UGFS
without manual compression of the groin (Table 2). An ethics
committee approved the study andwritten informed consent
was obtained from all patients. The study was conducted
according to the guidelines of the Declaration of Helsinki.
Treatment Modalities
UGFS
UGFS was performed in the outpatient clinic following the
European consensus guidelines.12 Duplex ultrasonography
with a 5e12 MHz probe (MyLab25 sonography apparatus,
Esaote Pie Medical Benelux B.V, Maastricht, the
Netherlands) was used to assess saphenous veins for
competence. The patient was placed in the supine position
and the patient’s leg was slightly elevated. The GSV was
then injected with foam using a 21 Gauge infusion cannula
about 5 cm above the knee under duplex guidance. The
needle was pulled back and the POLe99mTc foam was
injected. During the injection, the SF junction was manu-
ally compressed in three patients who did not undergo
surgery, until full vasospasm occurred and blood-flow
velocity decreased to zero. The duration of compression
was 4.75 min on average, starting at the time of injection.
In two patients, the SF junction was not compressed during
the injection of foam.
SF ligation
Patients were treated under local anaesthetic. The surgery
involved an incision in the groin creasemedial to the pulse ofTable 1 Half-life of polidocanol foam with and without 99mTc.
Measurement 1 Measurement2 M
Sclerosant T½ T1 T½ T1 T
Polidocanol foam 1.7 2.5 1.8 2.7 1
Polidocanol-99mTc
foam
1.8 2.7 1.7 2.7 1
T½ Z Time in which half of the original amount of liquid had reform
T1 Z Time in which the total amount of foam had reduced to liquid
SD Z Standard deviation.the femoral artery. The GSV was dissected up to its junction
with the common femoral vein. After identification of the
femoral vein, theGSVand all its tributaries at the SF junction
were ligated and divided. The incision was then closed. A
total of 14 days after surgery, we confirmed that the SF
junction had been successfully ligated using duplex ultraso-
nography. The patients were then treated with UGFS.
Scintigraphic imaging
For the visualisation of 99mTc, we used a single-head Siemens
Diacam gamma camera (Siemens Gammasonics, Hoffman
Estate, IL, USA) with a low-energy high-resolution collimator,
a 20% energy window around the 140 keV photo peak and
a dual-head Skylight gamma camera (Philips Medical Systems,
Best, the Netherlands). A dynamic study was started just
before injection, acquiring frames every 10 s for 10e15 min.
Analysis of Scintigraphic images
Image evaluation was performed using the standard
Siemens Icon computer platform. The analysis was per-
formed by first drawing regions of interest around veins
containing 99mTc activity and then generating timeeactivity
curves. The total 99mTc activity remaining in the GSV was
quantified as a function of time (Fig. 1). In addition, the
decrease per min of 99mTc activity in the GSV was calcu-
lated by fitting a linear trend line over the 2-min interval
directly after the peak using Microsoft Excel. The peak
activity was taken as 100%.
Results
In vitro experiment e measuring POLe99mTc versus
POL stability
Prior to treatment, POLe99mTc stability was measured
compared with POL 1% stability only (Table 1). The time that
was needed to re-form half of the POLe99mTc foam back into
liquid was 1.7 min on average (SDZ 0.1). The same time was
recorded for POL-only foam. For both mixtures, the time
until all foam had turned completely into liquid was 2.6 min
(SD Z 0.1). In conclusion, no differences in foam stability
were noted between POL with and without 99mTc.
In vivo experiment e treating the GSV with
POLe99mTc
In this experiment, five patients were treated for incom-
petence of the GSV with a POLe99mTc mixture only, three ofeasurement3 Measurement4 Average (SD)
½ T1 T½ T1 T½ T1
.7 2.6 1.8 2.7 1.7 (0.1) 2.6 (0.1)
.7 2.7 1.8 2.5 1.7 (0.1) 2.6 (0.1)
ed from the foam (in minutes).
(in minutes).
Table 2 Treatment characteristics of each patient.
Patient Treatment Compression of
SF junction
1 UGFS Yes
2 UGFS Yes
3 UGFS Yes
4 SFJ ligation þ UGFS No
5 SFJ ligation þ UGFS No
6 SFJ ligation þ UGFS No
7 UGFS No
8 UGFS No
Table 3 Reduction of 99mTc activity in GSV in percent-
point per minute and remaining 99mTc activity remaining
after 2.6 min following polidocanol-99mTc foam injection.
Patient Reduction
of 99mTc activity
(in %min1)
% 99mTc activity
2.6 min after
injection
Blocking the SFJ During Foam Sclerotherapy 775whom underwent manual compression of the SF junction
during foam injection. Another three patients underwent
SF ligation prior to POLe99mTc treatment. An average of
6.5 ml (5.5e10 ml) of sclerosing foam was used to treat the
GSV. Patients 1 and 2 received a split injection because
a larger amount of POLe99mTc foam was needed to achieve
full vasospasm. The radioactivity did not remain in the GSV
in all patients, despite blocking the SF junction by
compression or ligation (Fig. 1). The amount of radioac-
tivity was reduced by an average of 34% in the UGFS with
compression group 2.6 min after injection, leaving 66% of
pertechnetate activity in the GSV. In the ligation group,
pertechnetate activity was reduced by 57% after the same
time, leaving an average 99mTc of 43%. In the control group
(UGFS without compression), the nuclear activity showed
an average decrease of 72%, leaving 28% of pertechnetate
activity in the GSV. The rate of reduction during manual
compression of the SF junction was 17% per min. This rate
was 23% in the ligation group during the same time and 34%
in the control group (Table 3).
Discussion
Several authors have found indirect proof for systemic
distribution of sclerosant foam.13 This finding is consistent
with the results we describe in this article. However, until
now, no research has been done at the source of injection.
In this study, we demonstrate by imaging the GSV during
UGFS that foam does not stay in the treated vein. Although
the amount of foam floating into the femoral vein was not
completely prevented by manual compression or ligation of
the SF junction, the decrease in radioactivity was reducedFigure 1 Timeeactivity curves of 99mTc activity in GSV after
injection of sclerosans containing 99mTc-pertechnetate.in comparison to the control group. After 2.6 min, 99mTc
activity had reduced to 28% of the peak activity, indicating
that 72% had leaked away from the GSV in the control
group. In patients receiving compression or ligation, the
decrease in radioactivity was 55% of the peak activity,
indicating that 45% had leaked away from the GSV. As
demonstrated by our in vitro trials, it took 2.6 min for the
foam to be reduced to liquid. If this is the same in vivo, it
would mean that foam, and not liquid sclerosant, enters
the deep venous system during UGFS.
In our study,manual compression of the groin appeared to
be amore effectivemeasure than ligation of the SF junction,
althoughwe acknowledge that our observations are based on
the treatment of few patients. We propose that this differ-
enceoccurredbecause twoof threepatients in thefirst group
received a split injection. We hypothesise that due to the
vein spasm resulting from the first injection, the remaining
amount of foam was not able to leak away as quickly as in
patients, who received a single injection. This hypothesis
seems to be in agreement with the results of Yamaki et al.,14
who measured the amount of foam flowing to the deep
system using one or multiple injections. However, our result
could also have occurred because the second injectionmight
have levelled out the decline in 99mTc.
In vitro trials did not show a change in foam stability due
to the presence of 99mTc. This was to be expected because
99mTc is present in trace amounts only. Therefore, we do
not expect foam to have behaved differently due to the
addition of 99mTc. Nevertheless, a shortcoming of this study
is that POL was mixed instead of being labelled with
radioactivity. Theoretically, one cannot be certain that POL
and 99mTc travel together. However, considering the mass
transport that occurs in a flowing liquid, we think it is
unlikely that 99mTc would leak to the deep venous system,
whereas POL would not.
Our study results were in accordance with earlier find-
ings by Hill et al.15 Recently, Hill recorded echogenic
phenomena in the right half of the heart during UGFS.UGFS þ compression
1 9 89
2 7 82
3 36 27
Average 17 66
UGFS þ SFJ ligation
4 23 60
5 28 37
6 19 34
Average 23 43
UGFS control group
7 36 21
8 31 34
Average 34 28
776 R.P.M. Ceulen et al.During UGFS, the SF junction was compressed manually,
either with or without simultaneous leg elevation. The
intensity of the echogenic bolus observed was equal in both
groups.
In conclusion, on the basis of this study, we showed that
blockage of the SF junction by ligation or compression may
reduce, but does not completely stop, sclerosant foam from
entering the deep venous system.
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